Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

I. Krakowski · SciRah

Researcher profile · Semantic Scholar

I. Krakowski

Share profile

I. Krakowski — researcher profile on SciRah

h-index: 23
Works: 104
Citations: 3,065

Most-cited papers

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
G. Gravis, K. Fizazi, F. Joly, S. Oudard +29 more
2013The Lancet Oncology635 citations
Semantic Scholar
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
G. Gravis, J. Boher, F. Joly, M. Soulie +16 more
2016European Urology429 citations
Semantic Scholar
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
B. Chevallier, P. Fumoleau, P. Kerbrat, V. Diéras +6 more
1995Journal of Clinical Oncology230 citations
Semantic Scholar
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
K. Fizazi, L. Faivre, F. Lesaunier, R. Delva +27 more
2015The Lancet Oncology219 citations
Semantic Scholar
The official French guidelines to protect patients with cancer against SARS-CoV-2 infection
B. You, A. Ravaud, Anne Canivet, G. Ganem +7 more
2020The Lancet Oncology159 citations Open access
Semantic Scholar
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
G. Gravis, J. Boher, K. Fizazi, F. Joly +31 more
2015European Urology124 citations Open access
Semantic Scholar
Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma.
D. Belpomme, S. Gauthier, E. Pujade-Lauraine, T. Facchini +8 more
2000Annals of Oncology119 citations Open access
Semantic Scholar
Docetaxel reintroduction in patients with metastatic castration‐resistant docetaxel‐sensitive prostate cancer: a retrospective multicentre study
J. Eymard, S. Oudard, G. Gravis, J. Ferrero +7 more
2010BJU International96 citations
Semantic Scholar
Prevalence and incidence of chronic pain with or without neuropathic characteristics in patients with cancer
D. Bouhassira, É. Luporsi, I. Krakowski
2017Pain94 citations
Semantic Scholar
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
V. Diéras, B. Chevallier, P. Kerbrat, I. Krakowski +8 more
1996British Journal of Cancer90 citations Open access
Semantic Scholar
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
B. Bui, B. Chevallier, C. Chevreau, I. Krakowski +6 more
1995Journal of Clinical Oncology72 citations
Semantic Scholar
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
G. Gravis, P. Marino, F. Joly, S. Oudard +30 more
2014European Journal of Cancer68 citations
Semantic Scholar
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
P. Lavaud, G. Gravis, S. Foulon, F. Joly +34 more
2017European Urology64 citations
Semantic Scholar
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
K. Fizazi, F. Lesaunier, R. Delva, G. Gravis +24 more
2012European Journal of Cancer54 citations Open access
Semantic Scholar
Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.
G. Gravis, J. Boher, F. Joly, S. Oudard +16 more
201552 citations
Semantic Scholar
High-dose methotrexate and HELP [Holoxan (ifosfamide), Eldesine (vindesine), platinum] - doxorubicin in non-metastatic osteosarcoma of the extremity: A French multicentre pilot study
T. Philip, C. Iliescu, M. Demaille, H. Pacquement +7 more
199938 citations Open access
Semantic Scholar
Sexual health in cancer: the results of a survey exploring practices, attitudes, knowledge, communication, and professional interactions in oncology healthcare providers
T. Almont, F. Farsi, I. Krakowski, R. El Osta +2 more
2018Supportive Care in Cancer35 citations
Semantic Scholar
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial
S. Oudard, I. Latorzeff, A. Caty, L. Miglianico +24 more
2019JAMA Oncology31 citations Open access
Semantic Scholar
Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up.
K. Fizazi, A. Carmel, F. Joly, R. Delva +16 more
2018Annals of Oncology31 citations Open access
Semantic Scholar
Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck.
M. Degardin, P. Cappelaere, I. Krakowski, Pierre Fargeot +2 more
1996European Journal of Cancer Part B Oral Oncology30 citations
Semantic Scholar
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.
P. Blanchard, L. Faivre, F. Lesaunier, N. Salem +16 more
2016International Journal of Radiation Oncology, Biology, Physics29 citations
Semantic Scholar
[For a coordination of the supportive care for people affected by severe illnesses: proposition of organization in the public and private health care centres].
I. Krakowski, F. Boureau, R. Bugat, L. Chassignol +12 more
2004Bulletin du Cancer26 citations
Semantic Scholar
Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment
S. Antoun, H. Morel, P. Souquet, V. Surmont +7 more
2019Journal of Cachexia, Sarcopenia and Muscle25 citations Open access
Semantic Scholar
Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study.
D. Belpomme, I. Krakowski, M. Beauduin, T. Petit +6 more
2003Gynecologic Oncology22 citations
Semantic Scholar
Infection à SARS-CoV-2/COVID 19 et cancers solides : synthèse des recommandations à l’attention des professionnels de santé
Thomas Grellety, A. Ravaud, Anne Canivet, G. Ganem +7 more
2020Bulletin du Cancer19 citations Open access
Semantic Scholar
À propos de la mise en place des soins de support en cancérologie: pistes de réflexions et propositions
Philippe Colombat, S. Antoun, R. Aubry, Isabelle Banterla-Dadon +15 more
2008ONCOLOGIE19 citations
Semantic Scholar
Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup
N. Kerckhove, J. Busserolles, T. Stanbury, B. Pereira +6 more
2019BMJ Open18 citations Open access
Semantic Scholar
Supportive Care Organization in France: a national in-depth survey among patients and oncologists
F. Scotté, C. Hervé, P. Leroy, J. Tourani +11 more
2017Supportive Care in Cancer18 citations
Semantic Scholar
Radiofrequency ablation in palliative supportive care: early clinical experience.
F. Marchal, L. Brunaud, C. Bazin, Hervé Boccacini +4 more
2006Oncology Report18 citations Open access
Semantic Scholar
How Should Oncologists Choose an Electronic Patient-Reported Outcome System for Remote Monitoring of Patients With Cancer?
F. Denis, I. Krakowski
2021Journal of Medical Internet Research13 citations Open access
Semantic Scholar
[Standards, options and recommendations for the use of medical analgesics for the treatment of pain arising from excess nociception in adults with cancer (update 2002): opioid analgesics with the exception of morphine by mouth and the rotation].
S. Rostaing-Rigattieri, H. Rousselot, I. Krakowski, S. Theobald +22 more
2003Bulletin du Cancer12 citations
Semantic Scholar
[Standards, options and recommendations for the use of medical analgesics for the treatment of pain arising from excess nociception in adults with cancer (update 2002)].
I. Krakowski, S. Theobald, L. Balp, M. Bonnefoi +16 more
2002Bulletin du Cancer12 citations
Semantic Scholar
Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial.
K. Fizazi, A. Laplanche, F. Lesaunier, R. Delva +16 more
201411 citations
Semantic Scholar
[Recommendations for a successful cancer pain management in adults and children].
I. Krakowski, Y. Gestin, F. Jaulmes, F. Lakdja +15 more
1996Bulletin du Cancer10 citations
Semantic Scholar
[Full version of the 2005 Standards, Options and Recommendations for the management of procedure-related pain (lumbar puncture, bone marrow aspiration or biopsy, blood sampling) in adult patients with cancer].
I. Krakowski, S. Theobald, N. Fabre, T. Delorme +9 more
2005Bulletin du Cancer9 citations
Semantic Scholar
The benefit of combining docetaxel to androgen deprivation therapy in localized and metastatic castration-sensitive prostate cancer as predicted by ERG status: An analysis of two GETUG phase III trials.
S. Rajpar, A. Carmel, Zahira Merabet, P. Vielh +16 more
20178 citations
Semantic Scholar
Management of venous thromboembolism in cancer patients: the economic burden of hospitalizations
I. Mahé, D. Mayeur, I. Krakowski
2016Supportive Care in Cancer8 citations
Semantic Scholar
Granulocyte-colony-stimulating factor in elderly patients receiving chemotherapy for breast and gynaecological cancers: results of a French survey.
C. Falandry, I. Krakowski, H. Curé, É. Carola +3 more
2014Anticancer Research8 citations
Semantic Scholar
[Bisphosphonates, pain and quality of life in metastatic breast cancer patients: a literature review].
C. Roemer-Bécuwe, I. Krakowski, T. Conroy
2003Bulletin du Cancer7 citations
Semantic Scholar
High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fédération Nationale des Centres de Lutte contre le Cancer and Société Française d'Oncologie Pédiatrique.
T. Philip, C. Iliescu, M. Demaille, H. Pacquement +7 more
1999Annals of Oncology7 citations
Semantic Scholar
Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group.
H. Curé, I. Krakowski, A. Adenis, N. Tubiana +6 more
1998European Journal of Cancer7 citations
Semantic Scholar
[Supportive care for people affected by cancer: concept and management].
I. Krakowski
2006La Revue du praticien6 citations
Semantic Scholar
Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work
C. Falandry, I. Krakowski, H. Curé, É. Carola +4 more
2018Breast Cancer Research and Treatment5 citations
Semantic Scholar
Efficacy and tolerance of treatments received beyond progression in men with metastatic hormone-naive prostate cancer treated with androgen deprivation therapy (ADT) with or without docetaxel in the GETUG-AFU 15 phase III trial.
P. Lavaud, G. Gravis, Clémence Legoupil, F. Joly +16 more
20165 citations
Semantic Scholar
A study of ERG, PTEN, and ki-67 in a phase III trial assessing docetaxel and estramustine in high-risk localized prostate cancer (GETUG 12).
S. Rajpar, P. Vielh, A. Laplanche, F. Lesaunier +16 more
20145 citations
Semantic Scholar
[Coordinated organization of symptoms management and support in all the stages of cancer disease: putting in place pluridisciplinary structures of supportive oncological care].
I. Krakowski, C. Chardot, P. Bey, F. Guillemin +1 more
2001Bulletin du Cancer5 citations
Semantic Scholar
[Long term continuous combination of cisplatin and 5 fluorouracil in advanced breast neoplasms. A retrospective study of 77 patients].
D. Spaëth, T. Conroy, I. Krakowski, L. Geoffrois +3 more
1993Bulletin du Cancer5 citations
Semantic Scholar
[Adapted physical activity and metastatic cancer: What needs and expectations?]
T. Bouillet, F. Joly, M. Saghatchian, L. Guéroult-Accolas +3 more
2022Bulletin du Cancer4 citations Open access
Semantic Scholar
Genitourinary tumors, prostate
G. Gravis, K. Fizazi, F. J. Lobbedez, S. Oudard +16 more
20124 citations Open access
Semantic Scholar
[Radiofrequency ablation for palliation of soft tissue tumor pain].
R. Sanou, C. Bazin, I. Krakowski, H. Boccaccini +4 more
2010Journal de Radiologie4 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Ferrero×17
Invite
J. Ferrero — researcher profile on SciRah
G. Gravis×16
Invite
G. Gravis — researcher profile on SciRah
K. Fizazi×15
Invite
K. Fizazi — researcher profile on SciRah
R. Delva×15
Invite
R. Delva — researcher profile on SciRah

×15

Invite

F. Rolland — researcher profile on SciRah

C. Théodore×15

Invite

C. Théodore — researcher profile on SciRah

Invite

L. Mourey — researcher profile on SciRah

Invite

S. Oudard — researcher profile on SciRah

B. Laguerre×13

Invite

B. Laguerre — researcher profile on SciRah

M. Habibian×13

Invite

M. Habibian — researcher profile on SciRah

P. Beuzeboc×12

Invite

P. Beuzeboc — researcher profile on SciRah

Invite

F. Joly — researcher profile on SciRah